Ask Warren

Access Bio

950130 · KOSDAQ · ₩950130 · 엑세스바이오

₩1,920▼ ₩40 (2.04%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −52.71%
Market cap
₩68B
Enterprise value
₩67B
P/E
—
P/B
195.3×
Dividend yield
0.0%
ROE
−22.2%
Net margin
−474.1%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−59.2% from the high

₩1,777Today: ₩1,920 – ₩1,999₩4,705

Returns

  • 1W−2.0%
  • 1M−11.5%
  • 3M−6.3%
  • 6M−43.8%
  • YTD−49.5%
  • 1Y−52.7%
Volume today
20,207
0.1× the 20-day average
Traded today
₩39M
Listed shares
35,173,834
EPS (12 months)
−₩2
Earnings yield −0.1%
SellBuy
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

26Quiet
  • BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
  • MomentumWeak-13.9% over the last month; the price is below its 20-day average.
  • News impactSome3 news items and filings in two weeks; 0 rated high impact, 3 medium.

Signals describe activity, not recommendations. Not financial advice.

Access Bio stock overview

Access Bio (엑세스바이오, KRX: 950130) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops, manufactures and sells in-vitro diagnostic products based on immunochemical, biosensor and molecular diagnostic technologies, focusing on point-of-care rapid diagnostic tests. Its shares closed at ₩1,920 on Oct 29, 2026, down 2.04% on the day, giving it a market value of ₩68B.

Key facts

Market cap
₩68B
Sector
Biotech & Pharma
Latest price change
−2.04%
As of
Oct 29, 2026
Main business
The company develops, manufactures and sells in-vitro diagnostic products based on immunochemical, biosensor and molecular diagnostic technologies, focusing on point-of-care rapid diagnostic tests.

Quick answers about Access Bio

What does Access Bio do?
The company develops, manufactures and sells in-vitro diagnostic products based on immunochemical, biosensor and molecular diagnostic technologies, focusing on point-of-care rapid diagnostic tests. S. distributors for COVID-19 tests.
What is the market cap of Access Bio?
The market capitalisation of Access Bio was ₩68B at the close on Oct 29, 2026.
Who are the largest shareholders of Access Bio?
According to the latest official filings, the largest reported holders are PharmGen Science (24.71%, as of Jan 29, 2026); Park Hee-deok (0.10%, as of Jan 29, 2026); Lee Geun-hyeong (0.06%, as of Jan 29, 2026).
When is the next earnings report from Access Bio?
Korean companies rarely announce results dates in advance. Based on when Access Bio filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own Access Bio?
Yes. The National Pension Service held 0.00% of Access Bio shares as of Dec 31, 2020.

Company profile

The company develops, manufactures and sells in-vitro diagnostic products based on immunochemical, biosensor and molecular diagnostic technologies, focusing on point-of-care rapid diagnostic tests. Its main products are rapid tests for infectious diseases such as malaria, influenza and COVID-19, and its customers include governments and international agencies through tender markets in Africa and Southeast Asia, as well as U.S. distributors for COVID-19 tests.

Written by AI from the company's latest annual report.

Korean name
엑세스바이오
Sector
Biotech & Pharma
Themes
—
CEO
최영호
Founded
Sep 2002
Listed
May 2013
Listed shares
35,173,834
Fiscal year ends
Month 12
Website
www.accessbio.net

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Access Bio / 엑세스바이오 / 950130 / KRX:950130

Source: KRX statistical information